URMC’s groundbreaking Hodgkin Lymphoma study shows 92% survival rate
Written by Site Hub on October 19, 2024
A groundbreaking study from the University of Rochester Medical Center (URMC) on Hodgkin lymphoma has demonstrated a 92% survival rate, with fewer side effects and reduced use of radiation therapy. The study, led by Dr. Johnathan Friedberg and funded by the National Cancer Institute, involved around 1,000 pediatric and adult patients, marking the first U.S. trial of its kind.
The clinical trial tested two treatment regimens: one group received the standard chemotherapy (AVD) with an additional drug, while the other group received AVD alongside immune therapy. The results were so positive that the study was closed early, with the new regimen showing improved efficacy over the standard treatment.
Dr. Friedberg hopes the medical community will quickly adopt the new regimen and looks forward to further studies to better understand and address the small percentage of patients who are not cured.
Source: Rochester First
